DK0802800T3 - Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler - Google Patents

Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler

Info

Publication number
DK0802800T3
DK0802800T3 DK94925921T DK94925921T DK0802800T3 DK 0802800 T3 DK0802800 T3 DK 0802800T3 DK 94925921 T DK94925921 T DK 94925921T DK 94925921 T DK94925921 T DK 94925921T DK 0802800 T3 DK0802800 T3 DK 0802800T3
Authority
DK
Denmark
Prior art keywords
delivery
biologically active
active molecules
capsules containing
genetically altered
Prior art date
Application number
DK94925921T
Other languages
Danish (da)
English (en)
Inventor
E Edward Baetge
Joseph P Hammang
Frank T Gentile
Mark D Lindner
Shelley R Winn
Dwaine F Emerich
Original Assignee
Neurotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotech Sa filed Critical Neurotech Sa
Application granted granted Critical
Publication of DK0802800T3 publication Critical patent/DK0802800T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
DK94925921T 1993-08-12 1994-08-12 Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler DK0802800T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10527893A 1993-08-12 1993-08-12
PCT/US1994/009299 WO1995005452A2 (en) 1993-08-12 1994-08-12 Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules

Publications (1)

Publication Number Publication Date
DK0802800T3 true DK0802800T3 (da) 2002-10-07

Family

ID=22304946

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94925921T DK0802800T3 (da) 1993-08-12 1994-08-12 Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler

Country Status (13)

Country Link
US (4) US5656481A (de)
EP (2) EP1179350A3 (de)
JP (3) JP4098355B2 (de)
AT (1) ATE218893T1 (de)
AU (2) AU7568094A (de)
CA (1) CA2169292C (de)
DE (1) DE69430824T2 (de)
DK (1) DK0802800T3 (de)
ES (1) ES2178654T3 (de)
FI (1) FI960611L (de)
NO (1) NO960547L (de)
SG (1) SG48813A1 (de)
WO (1) WO1995005452A2 (de)

Families Citing this family (296)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
US5744327A (en) * 1990-02-20 1998-04-28 Board Of Regents, The University Of Texas System Methods for producing insulin in response to non-glucose secretagogues
US5792656A (en) * 1991-06-03 1998-08-11 Board Of Regents, The University Of Texas System Methods of preparing genetically engineered cells that produce insulin in response to glucose
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
AU7568094A (en) * 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5908623A (en) * 1993-08-12 1999-06-01 Cytotherapeutics, Inc. Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US5853717A (en) * 1994-07-20 1998-12-29 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
WO1996035446A1 (en) * 1995-05-12 1996-11-14 The Rockefeller University Treatment of alzheimer disease by modulation of synapsins
IN181898B (de) * 1995-06-07 1998-10-24 Cytotherapeutics Inc
US7364894B2 (en) * 1995-09-15 2008-04-29 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
WO1997012635A1 (en) * 1995-10-02 1997-04-10 Cytotherapeutics, Inc. Method for treating amyotrophic lateral sclerosis
US5855613A (en) 1995-10-13 1999-01-05 Islet Sheet Medical, Inc. Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US7297331B2 (en) * 1996-04-03 2007-11-20 The Rogosin Institute Beads containing restricted cancer cells producing material suppressing cancer cell proliferation
US6224912B1 (en) 1996-04-03 2001-05-01 The Rogo Institute Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
US6210664B1 (en) 1996-04-08 2001-04-03 New York University Medical Center Method for gene transfer to the central nervous system
AU2674097A (en) * 1996-04-17 1997-11-07 Cytotherapeutics, Inc. Method and device for delivery of apoptosis-inducing molecules
US7138251B1 (en) 1996-04-22 2006-11-21 Amgen Inc. Polynucleotides encoding a neurotrophic factor receptor
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US6054142A (en) 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US6150164A (en) * 1996-09-30 2000-11-21 The Regents Of The University Of Michigan Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
WO1998032458A1 (en) * 1997-01-23 1998-07-30 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
US5844077A (en) * 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
WO1998054213A2 (en) * 1997-05-30 1998-12-03 Amgen Inc. Neurotrophic factor receptors
WO1998057663A1 (en) 1997-06-17 1998-12-23 University Technology Corporation Neural transplantation for treating neurological disease
AU8180498A (en) * 1997-06-30 1999-01-19 Regents Of The University Of California, The Method for treatment of spinal cord injuries in a mammal
ZA986077B (en) 1997-07-09 2000-01-10 Genentech Inc ErbB4 receptor-specific neuregulin related ligands and uses therefor.
US6121415A (en) * 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
US6071748A (en) 1997-07-16 2000-06-06 Ljl Biosystems, Inc. Light detection device
US6469311B1 (en) 1997-07-16 2002-10-22 Molecular Devices Corporation Detection device for light transmitted from a sensed volume
US6994856B1 (en) 1997-07-24 2006-02-07 Genentech, Inc. ErbB4 receptor-specific neuregulin related ligands and uses therefor
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
US6042909A (en) * 1997-09-03 2000-03-28 Circe Biomedical, Inc. Encapsulation device
US7745142B2 (en) 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
US7632651B2 (en) 1997-09-15 2009-12-15 Mds Analytical Technologies (Us) Inc. Molecular modification assays
US7070921B2 (en) 2000-04-28 2006-07-04 Molecular Devices Corporation Molecular modification assays
US6326605B1 (en) 1998-02-20 2001-12-04 Ljl Biosystems, Inc. Broad range light detection system
US6825921B1 (en) 1999-11-10 2004-11-30 Molecular Devices Corporation Multi-mode light detection system
US6576476B1 (en) 1998-09-02 2003-06-10 Ljl Biosystems, Inc. Chemiluminescence detection method and device
US6992761B2 (en) 1997-09-20 2006-01-31 Molecular Devices Corporation Broad range light detection system
US6297018B1 (en) 1998-04-17 2001-10-02 Ljl Biosystems, Inc. Methods and apparatus for detecting nucleic acid polymorphisms
US6982431B2 (en) 1998-08-31 2006-01-03 Molecular Devices Corporation Sample analysis systems
US6156729A (en) * 1997-10-15 2000-12-05 California Institute Of Technology Leukemia inhibitory factor for use in modulating inflammation and pain
US6485901B1 (en) * 1997-10-27 2002-11-26 Boston Probes, Inc. Methods, kits and compositions pertaining to linear beacons
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
JP2002506830A (ja) 1998-03-13 2002-03-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療的ケモカイン受容体アンタゴニスト
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
US6303136B1 (en) 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
WO1999057248A1 (en) * 1998-04-30 1999-11-11 President And Fellows Of Harvard College Induction of neuronal regeneration
US5973119A (en) * 1998-06-05 1999-10-26 Amgen Inc. Cyclin E genes and proteins
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
WO2000004927A1 (en) * 1998-07-24 2000-02-03 Alleghney University Of The Health Sciences Allogeneic cellular immunogens useful as cancer vaccines
AU5667599A (en) 1998-07-27 2000-02-21 Ljl Biosystems, Inc. Apparatus and methods for time-resolved spectroscopic measurements
AU5223899A (en) 1998-07-27 2000-02-21 Ljl Biosystems, Inc. Apparatus and methods for spectroscopic measurements
US20020115213A1 (en) * 1998-08-14 2002-08-22 Northeastern Ohio Universities Of Medicine Engraftable neural progenitor & stem cells for brain tumor therapy
CZ300877B6 (cs) * 1998-09-09 2009-09-02 Myelos Corporation Lécivo pro lécení neurodegenerativních nebo myelinizacních poruch a virový vektor
KR20010079770A (ko) * 1998-09-09 2001-08-22 추후제출 프로사포신 수용체 활성을 자극하는 방법
US6344541B1 (en) * 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US6156514A (en) * 1998-12-03 2000-12-05 Sunol Molecular Corporation Methods for making recombinant cells
US6303749B1 (en) 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
DK1149114T3 (da) 1999-02-03 2014-06-23 Amgen Inc Polypeptider, der er involveret ved et immunrespons
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US6713293B1 (en) * 1999-02-08 2004-03-30 Friedrich Grummt Encapsulated cells containing an amplified expression vector as a drug delivery device
IL138990A0 (en) * 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
AU3005400A (en) 1999-02-23 2000-09-14 Ljl Biosystems, Inc. Frequency-domain light detection device
US6903244B1 (en) 1999-02-26 2005-06-07 University Of Utah Research Foundation Mice which are +/− or −/− for the elastin gene as models for vascular disease
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
AU3770800A (en) 1999-03-26 2000-10-16 Amgen, Inc. Beta secretase genes and polypeptides
US20070071734A1 (en) * 1999-04-06 2007-03-29 Weng Tao ARPE-19 as platform cell line for encapsulated cell-based delivery
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
US6521431B1 (en) 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
HK1049350B (en) 1999-08-05 2012-01-27 Abt Holding Company Multipotent adult stem cells and methods for isolation
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US6878543B1 (en) 1999-10-25 2005-04-12 Nsgene Sa Cultures of GFAP+ nestin+ cells that differentiate to neurons
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
RU2152800C1 (ru) * 1999-12-08 2000-07-20 Зыбин Дмитрий Владимирович Способ культивирования и модификации гетерогенных клеток млекопитающих
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US6458118B1 (en) 2000-02-23 2002-10-01 Medtronic, Inc. Drug delivery through microencapsulation
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
WO2002000710A2 (en) * 2000-06-28 2002-01-03 Amgen, Inc. B7-like molecules and uses thereof
JP2004519205A (ja) 2000-06-28 2004-07-02 アムジェン インコーポレイテッド 胸腺間質リンホポイエチンレセプター分子およびその使用
US6538010B1 (en) * 2000-11-08 2003-03-25 Research Triangle Institute Compounds and methods for promoting smoking cessation
WO2002044364A2 (en) 2000-11-28 2002-06-06 Amgen Inc. Polypeptides involved in immune response
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
WO2002092054A2 (en) * 2001-05-11 2002-11-21 Ortho-Mcneil Pharmaceutical, Inc. Immune modulation device for use in animals
WO2003000047A2 (en) * 2001-06-22 2003-01-03 Universite Catholique De Louvaine Hydrogel beads or capsules as artificial media for insects oviposition and rearing of endoparasitoids
EP1281767A3 (de) 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
US7332330B2 (en) 2001-09-11 2008-02-19 Renamed Biologics, Inc. Device for maintaining vascularization near an implant
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
DE10164039A1 (de) * 2001-12-28 2003-07-10 Nmi Univ Tuebingen Implantierbare Vorrichtung und deren Verwendung
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US7442546B2 (en) * 2002-03-15 2008-10-28 The Regents Of The University Of Michigan Method of modulating inflammatory response
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US8173372B2 (en) 2002-05-16 2012-05-08 Absorber Ab Methods of donor specific crossmatching
EP1369491A1 (de) * 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
KR101004086B1 (ko) * 2002-06-18 2010-12-27 에자이 알앤드디 매니지먼트 가부시키가이샤 유전자 치료용 초대 배양 지방세포
US7328069B2 (en) * 2002-09-06 2008-02-05 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by electrical stimulation of and the delivery of drugs to the left and right pudendal nerves
US7369894B2 (en) * 2002-09-06 2008-05-06 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by electrical stimulation of the sacral and/or pudendal nerves
US7276057B2 (en) * 2002-09-06 2007-10-02 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by drug delivery to the pudendal and sacral nerves
US7328068B2 (en) * 2003-03-31 2008-02-05 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by means of electrical stimulation of the pudendal and associated nerves, and the optional delivery of drugs in association therewith
US7427280B2 (en) 2002-09-06 2008-09-23 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7618948B2 (en) 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
AU2002952993A0 (en) 2002-11-29 2002-12-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic and diagnostic agents
US20040230182A1 (en) * 2002-12-27 2004-11-18 Medtronic, Inc. Drug delivery through encapsulation
US7732591B2 (en) * 2003-11-25 2010-06-08 Medtronic, Inc. Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
JP4742030B2 (ja) 2003-04-18 2011-08-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド ポリマーが結合したグリコシル化ニューブラスチン
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
AU2004238057B2 (en) 2003-05-16 2009-09-24 Universite Laval CNS chloride modulation and uses thereof
DE602004019524D1 (de) 2003-06-10 2009-04-02 Nsgene As Verbesserte sezernierung von neublastin
AU2004289953B2 (en) * 2003-06-18 2008-09-25 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
WO2005020677A1 (en) 2003-08-29 2005-03-10 The Walter And Eliza Hall Institute Of Medical Research Method of selecting animal models from animals which have been subject to mutagenesis, and the use of myb transcription factors for screening
KR20060095568A (ko) 2003-10-20 2006-08-31 엔에스진 에이/에스 파킨슨병의 생체내 유전자 요법
NZ547767A (en) 2003-12-24 2010-05-28 Inst Medical W & E Hall Therapeutic agents and uses therefor
ATE409741T1 (de) * 2004-01-19 2008-10-15 Nsgene As Nervenwachstumsfaktor sezernierende menschliche therapeutische zellen
US8467875B2 (en) 2004-02-12 2013-06-18 Medtronic, Inc. Stimulation of dorsal genital nerves to treat urologic dysfunctions
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
EP2289911A3 (de) 2004-03-30 2011-03-30 NsGene A/S Therapeutische Verwendung des Wachstumsfaktors nsg33
US8741635B2 (en) 2004-05-12 2014-06-03 The Walter And Eliza Hall Institute Of Medical Research Method of cell isolation
BRPI0511287A (pt) 2004-05-17 2007-12-04 Univ Minnesota uso de células-tronco do sangue do cordão umbilical para tratar evento isquêmico
US20090136552A1 (en) * 2004-07-30 2009-05-28 Mette Gronborg Growth factors nsg28, nsg30, and nsg32
PT1786454E (pt) 2004-08-19 2010-08-18 Biogen Idec Inc Variantes de neublastina
CN101123978B (zh) 2004-08-19 2012-12-12 比奥根艾迪克Ma公司 神经胚素变体
US20060099193A1 (en) * 2004-10-22 2006-05-11 Ikuko Sugaya Methods and materials for suppressing pain
MX2007012155A (es) 2005-04-01 2008-04-04 Nsgene As Linea celular precursora neural inmortalizada humana.
US20060253068A1 (en) * 2005-04-20 2006-11-09 Van Bilsen Paul Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart
KR101504622B1 (ko) 2005-04-29 2015-03-20 에이전시 포 사이언스, 테크놀로지 앤드 리서치 고차가지구조 고분자 및 그들의 응용
US20060257368A1 (en) * 2005-05-03 2006-11-16 Clemson University Devices and methods for improved viability of cells
CA2606858A1 (en) * 2005-05-03 2006-11-09 Veterinarmedizinische Universitat Wien Permeable capsules
US7902352B2 (en) * 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
WO2006121960A2 (en) * 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
AU2006246826B2 (en) 2005-05-17 2011-01-06 Gloriana Therapeutics Sarl An implantable therapy system for treating a living being with an active factor
US20090169523A1 (en) 2005-06-13 2009-07-02 Catherine Verfaillie Hsc self-renewal
DK2407484T3 (en) 2005-06-24 2016-09-05 The Walter And Eliza Hall Inst Of Medical Res Therapeutic pro-apoptotic BH3-like molecules, and methods of generating and / or selecting those
US9133517B2 (en) * 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
US20080280843A1 (en) * 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
US8357666B2 (en) 2005-08-01 2013-01-22 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through RNA interference
EP1919954B1 (de) 2005-08-30 2016-10-19 University of Miami Immunmodulierende tumornekrosefaktor-rezeptor-25 (tnfr25)-agonisten, antagonisten und immuntoxine
WO2008048671A1 (en) * 2006-10-18 2008-04-24 University Of Illinois Embryonic-like stem cells derived from adult human peripheral blood and methods of use
US9388382B2 (en) * 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
US20080286250A1 (en) * 2005-10-28 2008-11-20 Jens Tornoe Implantable Biocompatible Immunoisolatory Vehicle for Delivery of Gdnf
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US10117900B2 (en) * 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
HRP20150691T1 (hr) 2005-11-18 2015-11-06 Glenmark Pharmaceuticals S.A. Anti-alfa2 integrin protutijela i njihova uporaba
WO2007078922A2 (en) 2005-12-30 2007-07-12 Neurotech Usa Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
PL1981515T3 (pl) 2006-01-23 2014-02-28 Athersys Inc Leczenie urazów i chorób mózgu za pomocą MAPC
EP2392339A1 (de) * 2006-01-23 2011-12-07 Athersys, Inc. MAPC-Therapeutika ohne begleitende Immunsuppression
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP2013331A2 (de) 2006-04-14 2009-01-14 Advanced Cell Technology, Inc. Hämangiokolonie bildende zellen
US20070255333A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Neuromodulation therapy for perineal or dorsal branch of pudendal nerve
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US9717775B2 (en) 2006-07-18 2017-08-01 University Of Utah Research Foundation Methods for treating pain and screening analgesic compounds
US20080039415A1 (en) * 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US7819842B2 (en) * 2006-11-21 2010-10-26 Medtronic, Inc. Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites
US7988668B2 (en) * 2006-11-21 2011-08-02 Medtronic, Inc. Microsyringe for pre-packaged delivery of pharmaceuticals
US20080171906A1 (en) * 2007-01-16 2008-07-17 Everaerts Frank J L Tissue performance via hydrolysis and cross-linking
WO2008112701A2 (en) * 2007-03-15 2008-09-18 The Mclean Hospital Corporation G-substrate for the treatment and prevention of parkinson's disease
JP5967861B2 (ja) 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
US20090098055A1 (en) 2007-08-23 2009-04-16 Intrexon Corporation Methods and Compositions for Diagnosing Disease
WO2009029508A1 (en) * 2007-08-28 2009-03-05 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute, Inc. Intracranial catheter and methods of use
JP2010540534A (ja) 2007-09-28 2010-12-24 イントレキソン コーポレーション 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
SI2592148T1 (sl) 2007-10-12 2018-12-31 F. Hoffmann-La Roche Ag Izražanje beljakovin iz več nukleinskih kislin
CN101978047A (zh) 2008-01-18 2011-02-16 明尼苏达大学董事会 干细胞聚集体及制备和使用方法
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
WO2009125332A1 (en) * 2008-04-07 2009-10-15 Peter Bromley New and safe procedure for immunization against infectious diseases agents
KR20110006672A (ko) 2008-04-07 2011-01-20 뉴포텐셜, 인크. Ｈｄａｃ 조절제의 사용을 통한 다능 유전자의 유도에 의한 세포 재프로그래밍
CA2722693C (en) 2008-05-06 2023-03-21 Advanced Cell Technology, Inc. Hemangio colony forming cells and non-engrafting hemangio cells
JP5748654B2 (ja) 2008-05-06 2015-07-15 オカタ セラピューティクス， インコーポレイテッド 多能性幹細胞に由来する除核赤血球細胞を産生するための方法
US8586558B2 (en) * 2008-05-16 2013-11-19 The Mclean Hospital Corporation RAB3B for treatment and prevention of Parkinson's disease
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CN102164611B (zh) 2008-07-24 2015-01-07 Ns基因公司 生长因子metrnl的治疗用途
US9446168B2 (en) 2010-06-07 2016-09-20 Beta-O2 Technologies Ltd. Multiple-layer immune barrier for donor cells
US9540630B2 (en) * 2008-09-17 2017-01-10 Beta O2 Technologies Ltd. Optimization of alginate encapsulation of islets for transplantation
US20100158878A1 (en) 2008-12-23 2010-06-24 Alexandra Capela Target populations of oligodendrocyte precursor cells and methods of making and using same
WO2010083842A2 (en) 2009-01-23 2010-07-29 Nsgene A/S Expression of neuropeptides in mammalian cells
EP2389435B1 (de) * 2009-01-23 2015-11-04 NsGene A/S Verbesserte zelllinien und ihre verwendung für verkapselte zell-bio-abgabe
WO2010111278A1 (en) 2009-03-23 2010-09-30 The Texas A&M University System Compositions of mesenchymal stem cells to regenerate bone
CA2759244A1 (en) * 2009-04-23 2010-10-28 Neurotech Usa, Inc. Cell lines that produce prostaglandin f2 alpha (pgf2a) and uses thereof
SG10201402038WA (en) 2009-05-05 2014-07-30 Amgen Inc FGF21 Mutants And Uses Thereof
BRPI0902039B8 (pt) 2009-06-09 2021-05-25 Anhanguera Educacional Ltda composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais
SG178125A1 (en) 2009-08-03 2012-03-29 Univ Miami Method for in vivo expansion of t regulatory cells
ES2783024T3 (es) 2009-09-29 2020-09-16 Univ Gent Hidrólisis de la unión de manosa-1-fosfo-6-manosa a fosfo-6-manosa
CA2776748A1 (en) * 2009-10-08 2011-04-14 Neurotech Usa, Inc. Use of pedf in an encapsulated cell-based delivery system
BR112012011980A2 (pt) 2009-11-19 2021-09-08 Oxyrane Uk Limited Métodos de produzir células transformadas de yarrowia lipolytica e proteínas-alvocompreendendo n-glicanos, células transformadas de yarrowia lipolytica e suas culturas, bem como composição compreendendo glicoproteínas
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2515864A4 (de) * 2009-12-23 2013-09-11 Psivida Inc Vorrichtung mit verzögerter freisetzung
SG10201501402UA (en) 2010-02-25 2015-04-29 Abt Holding Co Modulation of macrophage activation
ES2703428T3 (es) 2010-02-25 2019-03-08 Abt Holding Co Modulación de la angiogénesis
JP2013523184A (ja) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
WO2011139688A2 (en) 2010-04-28 2011-11-10 The J. David Gladstone Institutes Methods for generating cardiomyocytes
SG185526A1 (en) 2010-05-12 2012-12-28 Abt Holding Co Modulation of splenocytes in cell therapy
EP3399026B1 (de) 2010-06-14 2024-06-26 The Scripps Research Institute Neuprogrammierung von zellen für ein neues zellschicksal
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
US9475709B2 (en) 2010-08-25 2016-10-25 Lockheed Martin Corporation Perforated graphene deionization or desalination
JP6151183B2 (ja) 2010-09-29 2017-06-21 オキシレイン ユーケー リミテッド マンノース−１−ホスホ−６−マンノース結合からキャップを外すことおよびリン酸化ｎ−グリカンを脱マンノシル化することができるマンノシダーゼならびに哺乳動物細胞による糖タンパク質の取り込みを促進する方法
EP2622089B1 (de) 2010-09-29 2023-11-01 Oxyrane UK Limited Demannosylierung von phosphorylierten n-glycanen
KR101886029B1 (ko) 2010-10-01 2018-08-07 호바 세라퓨틱스 에이피에스 무해자극통증, 통각과민증, 자발통증 및 헛통증의 치료를 위한 메테오린의 용도
US8815942B2 (en) 2010-10-20 2014-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
CA2820622A1 (en) 2010-12-02 2012-06-07 Neurotech Usa, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
EP2717899A4 (de) 2011-06-06 2015-07-29 Kineta One Llc Pharmazeutische zusammensetzungen auf shk-basis sowie verfahren zu ihrer herstellung und verwendung
JP6145667B2 (ja) 2011-09-05 2017-06-14 ホーバ セラピューティクス アンパルトセルスカブ アロディニア、痛覚過敏、自発痛、及び幻痛の治療
EP2825193B1 (de) 2012-03-15 2019-11-13 Oxyrane UK Limited Verfahren und materialien zur behandlung von morbus pompe
US10118130B2 (en) 2016-04-14 2018-11-06 Lockheed Martin Corporation Two-dimensional membrane structures having flow passages
US9834809B2 (en) 2014-02-28 2017-12-05 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
US10418143B2 (en) 2015-08-05 2019-09-17 Lockheed Martin Corporation Perforatable sheets of graphene-based material
US9844757B2 (en) 2014-03-12 2017-12-19 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US10653824B2 (en) 2012-05-25 2020-05-19 Lockheed Martin Corporation Two-dimensional materials and uses thereof
US9744617B2 (en) 2014-01-31 2017-08-29 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
US9610546B2 (en) 2014-03-12 2017-04-04 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
WO2013181424A1 (en) 2012-05-30 2013-12-05 Neurotech Usa, Inc. Cryopreserved implantable cell culture devices and uses thereof
WO2014022376A2 (en) 2012-08-01 2014-02-06 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
CA2880808C (en) 2012-08-01 2023-01-24 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
KR20210041631A (ko) 2013-01-09 2021-04-15 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
WO2014110094A1 (en) 2013-01-09 2014-07-17 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
EP2964758B1 (de) 2013-03-05 2020-05-27 Oxyrane UK Limited Herstellung von katalytisch aktiver typ-i-sulfatase
AU2014225352B2 (en) 2013-03-07 2017-02-09 Viacyte, Inc. 3-dimensional large capacity cell encapsulation device assembly
USD720469S1 (en) 2013-03-07 2014-12-30 Viacyte, Inc. Cell encapsulation device
WO2014164621A1 (en) 2013-03-12 2014-10-09 Lockheed Martin Corporation Method for forming filter with uniform aperture size
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
CA2909267C (en) 2013-04-12 2022-10-25 Saverio LA FRANCESCA Improving organs for transplantation
EP2992088B1 (de) 2013-04-30 2019-08-21 Katholieke Universiteit Leuven Zelltheraphie für myelodysplastische syndrome
CN105377286B (zh) 2013-05-31 2021-07-02 犹他大学研究基金会 芋螺毒素(conotoxin)肽，其医药组合物和用途
US9572918B2 (en) 2013-06-21 2017-02-21 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
AU2014318846A1 (en) 2013-09-11 2016-03-10 Neurotech Usa, Inc. Encapsulated cell therapy cartridge
WO2015042580A1 (en) 2013-09-23 2015-03-26 Biogen Idec Ma Inc. Compositions and methods for treatment of neuropathic pain
SG11201606287VA (en) 2014-01-31 2016-08-30 Lockheed Corp Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer
SG11201606289RA (en) 2014-01-31 2016-08-30 Lockheed Corp Perforating two-dimensional materials using broad ion field
EA201790508A1 (ru) 2014-09-02 2017-08-31 Локхид Мартин Корпорейшн Мембраны гемодиализа и гемофильтрации на основе двумерного мембранного материала и способы их применения
US20170266354A1 (en) * 2014-09-04 2017-09-21 Kemijski Institut Cell-Based Device For Local Treatment With Therapeutic Protein
US10456356B2 (en) 2015-05-27 2019-10-29 Neurotech Usa, Inc. Use of encapsulated cell therapy for treatment of ophthalmic disorders
KR20180037991A (ko) 2015-08-06 2018-04-13 록히드 마틴 코포레이션 그래핀의 나노 입자 변형 및 천공
US10617738B2 (en) 2015-10-27 2020-04-14 The University Of Queensland Mammalian EphA4 polypeptide derivatives lacking one or more N-glycosylation sites and method of use thereof
KR20190019907A (ko) 2016-04-14 2019-02-27 록히드 마틴 코포레이션 자유-플로팅 방법을 사용한 대규모 이송을 위한 그래핀 시트 취급 방법
WO2017180135A1 (en) 2016-04-14 2017-10-19 Lockheed Martin Corporation Membranes with tunable selectivity
KR20190018411A (ko) 2016-04-14 2019-02-22 록히드 마틴 코포레이션 그래핀 결함의 선택적 계면 완화
SG11201808961QA (en) 2016-04-14 2018-11-29 Lockheed Corp Methods for in situ monitoring and control of defect formation or healing
WO2017180134A1 (en) 2016-04-14 2017-10-19 Lockheed Martin Corporation Methods for in vivo and in vitro use of graphene and other two-dimensional materials
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
SG11201811763SA (en) 2016-07-18 2019-02-27 Eth Zuerich B-cell-mimetic cells
EP3272877A1 (de) 2016-07-18 2018-01-24 ETH Zurich B-zell-mimetische zellen
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
CA3041514A1 (en) 2016-10-24 2018-05-03 United Therapeutics Corporation Enhancement of msc immunomodulatory properties by treprostinil
CN110167455B (zh) 2016-11-10 2022-10-11 韦尔赛特公司 含有pdx1胰腺内胚层细胞的细胞递送装置及其方法
KR20210132207A (ko) 2017-03-10 2021-11-03 에프. 호프만-라 로슈 아게 다중특이적 항체의 생산 방법
US11304893B2 (en) 2017-07-24 2022-04-19 California Institute Of Technology Low power, chemically amplified, electrically removable barrier
EP3656851A1 (de) 2018-11-23 2020-05-27 Technische Universität Dresden Künstliche hla-positive feeder-zelllinien für nk-zellen und verwendungen davon
US12133870B2 (en) 2019-03-19 2024-11-05 Spinalcyte Llc Treatment of opioid addiction using fibroblasts and products thereof
AR120309A1 (es) 2019-10-28 2022-02-09 Medimmune Ltd Formulaciones de polvo seco de anticuerpos que se unen a la linfopoyetina del estroma tímico (tslp) y métodos de uso de las mismas
WO2022011081A1 (en) 2020-07-09 2022-01-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cell lines that produce human retinoschisin proteins and uses thereof
US11644756B2 (en) * 2020-08-07 2023-05-09 KLA Corp. 3D structure inspection or metrology using deep learning
WO2022081760A1 (en) 2020-10-14 2022-04-21 Sana Biotechnology, Inc. Hepatocyte-like cells
IT202100006569A1 (it) 2021-03-18 2022-09-18 Hemera S R L Metodo per ottenere macrofagi rigenerativi educati dal tumore e loro uso nella medicina rigenerativa
WO2023081420A1 (en) 2021-11-05 2023-05-11 Abt Holding Company Culture-expanded canine progenitor cells and related methods
CN116077817B (zh) * 2021-12-06 2025-08-26 清源泰硕(北京)医疗器械有限公司 一种用于局部放疗的凝胶制剂注射系统
EP4482465A2 (de) 2022-02-25 2025-01-01 ViaCyte, Inc. Mehrschichtige implantierbare zellverkapselungsvorrichtungen und verfahren dafür

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3093831A (en) * 1959-10-22 1963-06-18 Jordan Gerhard Paul Wilhelm Artificial gland
US3615024A (en) * 1968-08-26 1971-10-26 Amicon Corp High flow membrane
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4409331A (en) * 1979-03-28 1983-10-11 Damon Corporation Preparation of substances with encapsulated cells
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
NO163060C (no) * 1981-03-13 1990-03-28 Damon Biotech Inc Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer.
JPS59501747A (ja) * 1982-09-29 1984-10-18 スピ−ルバ−グ　セオドア−　イ− カプセル封入された、治療物質産生性の遺伝子操作された生物
US4470461A (en) * 1982-09-30 1984-09-11 Phillips Petroleum Company Organic nitro compounds as cosurfactants in enhanced oil recovery processes
EP0127989A3 (de) * 1983-06-01 1986-03-26 Connaught Laboratories Limited Mikroverkapselung von lebenden Gewebe und Zellen
US4689293A (en) * 1983-06-06 1987-08-25 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4806355A (en) * 1983-06-06 1989-02-21 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4749620A (en) * 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
US4686098A (en) * 1984-05-14 1987-08-11 Merck & Co., Inc. Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
GB8500121D0 (en) * 1985-01-03 1985-02-13 Connaught Lab Microencapsulation of living cells
US4868121A (en) * 1985-02-07 1989-09-19 Mcdonnell Douglas Corporation Islet isolation process
US4902295A (en) * 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4753635A (en) * 1986-05-23 1988-06-28 Jacqueline Sagen Inducing analgesia by implantation of cells releasing neuroactive substances
US5026365A (en) * 1987-04-29 1991-06-25 The University Of Massachusetts Method and apparatus for therapeutically treating immunological disorders and disease states
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US4942129A (en) * 1987-07-28 1990-07-17 Queen's University At Kingston Multiple membrane microencapsulation
EP0301777A1 (de) * 1987-07-28 1989-02-01 Queen's University At Kingston Multiple Membran-Mikroenkapselung
US5049493A (en) * 1987-10-23 1991-09-17 California Institute Of Technology Enhancement of cell growth by expression of a cloned hemoglobin gene
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
GB8809129D0 (en) * 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5002661A (en) * 1989-08-25 1991-03-26 W. R. Grace & Co.-Conn. Artificial pancreatic perfusion device
WO1991007951A1 (en) * 1989-12-05 1991-06-13 Trancel Corporation Homologous guluronic acid alginate coating composition for in-vivo application and implantation and method of using same
WO1991009119A1 (en) * 1989-12-13 1991-06-27 Trancel Corporation Improved alginate microcapsules, methods of making and using same
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5084350A (en) * 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5167762A (en) * 1991-01-02 1992-12-01 Micron Technology, Inc. Anisotropic etch method
SG47470A1 (en) * 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
WO1993002635A1 (en) * 1991-07-30 1993-02-18 Baxter International Inc. Foramenous implant
DE69328730T2 (de) * 1992-02-14 2000-09-28 Regeneron Pharmaceuticals, Inc. Vorbeugung von verletzungen und degenerationen von photorezeptoren durch neurotrophische faktoren
AU7568094A (en) * 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules

Also Published As

Publication number Publication date
WO1995005452A2 (en) 1995-02-23
EP0802800A2 (de) 1997-10-29
WO1995005452A3 (en) 1995-03-30
DE69430824D1 (de) 2002-07-18
US5676943A (en) 1997-10-14
JPH09508002A (ja) 1997-08-19
ES2178654T3 (es) 2003-01-01
DE69430824T2 (de) 2003-01-23
EP1179350A3 (de) 2003-01-02
JP2008133285A (ja) 2008-06-12
NO960547L (no) 1996-04-12
FI960611A7 (fi) 1996-04-09
FI960611L (fi) 1996-04-09
EP1179350A2 (de) 2002-02-13
US5639275A (en) 1997-06-17
JP4524230B2 (ja) 2010-08-11
AU9718498A (en) 1999-03-04
US5653975A (en) 1997-08-05
ATE218893T1 (de) 2002-06-15
AU7568094A (en) 1995-03-14
NO960547D0 (no) 1996-02-12
JP2006063081A (ja) 2006-03-09
CA2169292C (en) 2010-11-23
AU717663B2 (en) 2000-03-30
SG48813A1 (en) 1998-05-18
FI960611A0 (fi) 1996-02-09
US5656481A (en) 1997-08-12
CA2169292A1 (en) 1995-02-23
EP0802800B1 (de) 2002-06-12
JP4098355B2 (ja) 2008-06-11

Similar Documents

Publication Publication Date Title
DK0802800T3 (da) Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler
DK0663817T3 (da) Celleindkapslingsindretning
CA2090719A1 (en) In vivo delivery of active factors by co-cultured cell implants
NO891909D0 (no) Implantat for brytningskorreksjon i et oeyes forkammer.
DK0585368T3 (da) Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
DK0849990T3 (da) Populationer af hvilende celler til kerneoverføring
DK463586A (da) Fsh
ATE350068T1 (de) Terminal-sterilisierte osteogene vorrichtungen und ihre herstellung
NO902195L (no) In vivo avgivelse av neurotransmittere med implanterte, innkapslede celler.
EP0269745A4 (de) Knochenimplantat.
DK0474382T3 (da) Elektrokemiske celler, som hovedsgelig er fri for kviksølv
ATE89485T1 (de) Neurologisches therapiesystem.
DE69432865D1 (de) Implantierbare prothese, kit und vorrichtung zu deren herstellung
ATE76331T1 (de) Mikroenkapsulierung von biologisch aktivem material.
AU1356395A (en) Prosthetic implant manufacture
NO974811D0 (no) CNS-utvekstmodulatorer, preparater, celler og fremgangsmåter som omfatter og anvender slike
FR2597091B1 (fr) Implants permanents biologiquement actifs
AU2148201A (en) Particulate construct for use in the transplantation field
ATA225793A (de) Modulares, universell anwendbares implantatsystem mit dazugehörigem instrumentarium
BR9105546A (pt) Implante coclear com transmissao otica atraves da membrana timpanica
UA5341A1 (uk) Цифрова комутаційна система
ATE101996T1 (de) Implantierbare hueftgelenksprothese.
DE69532688D1 (de) Brustimplantat mit ablenkelementen
NO881941D0 (no) Benimplantasjon.
SE9302402D0 (sv) Fysiologisk loesning foer foervaring och odling av gameter, celler, vaevnader och organ